Boston Scientific
BSX
$46.73
+1.59%
Boston Scientific Corp. is a global medical device company specializing in less invasive technologies across interventional cardiology, rhythm management, endoscopy, urology, and neuromodulation. It holds a strong competitive position as a diversified innovator in the medical devices industry, with a broad portfolio that addresses multiple high-growth therapeutic areas. The current investor narrative centers on the company's strategic pivot into the transcatheter aortic valve replacement (TAVR) market through a $1.5 billion investment in MiRus, which has captured Wall Street's attention, while the stock has experienced a severe drawdown of over 60% from its 52-week high, raising debates about valuation and growth sustainability amid mixed clinical trial results and broader market volatility.…
BSX
Boston Scientific
$46.73
Related headlines
BSX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Boston Scientific's 12-month outlook, with a consensus price target around $62.69 and implied upside of +34.1% versus the current price.
Average Target
$62.69
0 analysts
Implied Upside
+34.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$44 - $94
Analyst target range
The target price range spans from a low of $50.00 to a high of $94.00, with the high target suggesting a potential upside of 101% from the current price, likely assuming successful TAVR market penetration and strong revenue growth. The low target of $50.00 implies a modest 7% upside, reflecting concerns about competitive pressures or slower-than-expected adoption of new products. The wide spread between the low and high targets indicates significant uncertainty about the company's future performance, but the overall bullish consensus and recent ratings actions suggest that analysts view the current price as an attractive entry point.
BSX Technical Analysis
Boston Scientific's stock is in a pronounced downtrend, with a 1-year price change of -55.46% and a 6-month decline of -50.04%. The current price of $46.73 sits near the lower end of its 52-week range, at approximately 42.7% of the range (calculated as (46.73 - 42.2) / (109.5 - 42.2) * 100), indicating that the stock is trading close to its 52-week low of $42.20. This positioning suggests that the market is pricing in significant negative sentiment, and the stock remains in a bearish phase with no clear signs of a trend reversal.
Beta
0.58
0.58x market volatility
Max Drawdown
-60.6%
Largest decline past year
52-Week Range
$42-$110
Price range past year
Annual Return
-55.5%
Cumulative gain past year
| Period | BSX Return | S&P 500 |
|---|---|---|
| 1m | +8.5% | +0.3% |
| 3m | -17.3% | +4.0% |
| 6m | -50.0% | +8.3% |
| 1y | -55.5% | +20.2% |
| ytd | -50.7% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BSX Fundamental Analysis
Boston Scientific's revenue trajectory remains robust, with Q1 2026 revenue of $5.203 billion, representing an 11.58% year-over-year growth rate. This growth is consistent with the prior quarters, as Q4 2025 revenue was $5.286 billion and Q3 2025 was $5.065 billion, showing a stable growth pattern. The company's cardiovascular segment, which generated $3.493 billion in revenue, is the primary growth driver, while the MedSurg segment contributed $1.814 billion. The sustained double-digit growth indicates strong demand for its innovative medical devices, supporting the investment case despite the stock's poor price performance.
Quarterly Revenue
$5.2B
2026-03
Revenue YoY Growth
+11.6%
YoY Comparison
Gross Margin
69.4%
Latest Quarter
Free Cash Flow
$3.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BSX Overvalued?
Given that Boston Scientific has positive net income, the PE ratio is the primary valuation metric. The trailing PE is 48.65x, while the forward PE is 13.54x, a significant gap that implies the market expects a substantial earnings increase in the next year. This gap is unusually wide and may reflect one-time charges or a low current EPS due to recent acquisitions, but it also suggests that the market is pricing in a strong earnings recovery. The PEG ratio of 0.88 indicates that the stock is trading at a discount to its expected growth rate, which could be attractive to growth investors.
PE
48.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 17x~88x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.7x
Enterprise Value Multiple